Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,823 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Matsumoto T, Yamamoto Y, Kotaka M, Masuishi T, Tsuji Y, Shoji H, Hirata K, Tsuduki T, Makiyama A, Izawa N, Takahashi N, Tsuda M, Yasui H, Ohta T, Kito Y, Otsu S, Hironaka S, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K. Matsumoto T, et al. Among authors: tsuji y. Target Oncol. 2024 Mar;19(2):181-190. doi: 10.1007/s11523-024-01043-2. Epub 2024 Mar 1. Target Oncol. 2024. PMID: 38427280 Free PMC article. Clinical Trial.
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
Sunakawa Y, Kuboki Y, Watanabe J, Terazawa T, Kawakami H, Yokota M, Nakamura M, Kotaka M, Sugimoto N, Ojima H, Oki E, Kajiwara T, Yamamoto Y, Tsuji Y, Denda T, Tamura T, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T. Sunakawa Y, et al. Among authors: tsuji y. Target Oncol. 2024 Jan;19(1):59-69. doi: 10.1007/s11523-023-01027-8. Epub 2024 Jan 9. Target Oncol. 2024. PMID: 38194163 Free PMC article. Clinical Trial.
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
Yamamoto S, Nagashima K, Kawakami T, Mitani S, Komoda M, Tsuji Y, Izawa N, Kawakami K, Yamamoto Y, Makiyama A, Yamazaki K, Masuishi T, Esaki T, Nakajima TE, Okuda H, Moriwaki T, Boku N. Yamamoto S, et al. Among authors: tsuji y. BMC Cancer. 2021 Oct 29;21(1):1159. doi: 10.1186/s12885-021-08890-6. BMC Cancer. 2021. PMID: 34715820 Free PMC article.
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.
Yoshino T, Yamazaki K, Shinozaki E, Komatsu Y, Nishina T, Baba H, Tsuji A, Tsuji Y, Yamaguchi K, Sugimoto N, Denda T, Muro K, Takayama T, Esaki T, Hamamoto Y, Moriwaki T, Shimada Y, Goto M, Nakayama N, Fujii H, Tanase T, Ohtsu A. Yoshino T, et al. Among authors: tsuji a, tsuji y. Clin Colorectal Cancer. 2018 Dec;17(4):e719-e732. doi: 10.1016/j.clcc.2018.07.009. Epub 2018 Jul 26. Clin Colorectal Cancer. 2018. PMID: 30172759 Free article.
aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K. Fujita Y, et al. Among authors: tsuji a, tsuji y. Oncologist. 2019 Mar;24(3):327-337. doi: 10.1634/theoncologist.2018-0119. Epub 2018 Nov 13. Oncologist. 2019. PMID: 30425180 Free PMC article. Clinical Trial.
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A. Yoshino T, et al. Among authors: tsuji a, tsuji y. Lancet Oncol. 2012 Oct;13(10):993-1001. doi: 10.1016/S1470-2045(12)70345-5. Epub 2012 Aug 28. Lancet Oncol. 2012. PMID: 22951287 Clinical Trial.
Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial.
Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, Saito H, Iwase H, Tsuji Y, Tamura T, Yamamoto S, Yoshida S. Yamao T, et al. Among authors: tsuji y. Jpn J Clin Oncol. 2004 Jun;34(6):316-22. doi: 10.1093/jjco/hyh063. Jpn J Clin Oncol. 2004. PMID: 15333683 Clinical Trial.
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y, Shinozaki K, Fujiwara T, Mizushima T, Harihara Y, Nagata N, Kurihara N, Ando M, Kusakawa G, Sakai T, Uchida Y, Takamoto M, Kimoto S, Hyodo I. Kotaka M, et al. Among authors: tsuji y. Cancer Chemother Pharmacol. 2020 Nov;86(5):607-618. doi: 10.1007/s00280-020-04135-8. Epub 2020 Sep 23. Cancer Chemother Pharmacol. 2020. PMID: 32965539 Free PMC article. Clinical Trial.
1,823 results